So MDS/MPN and overlap syndromes are a group of cancers that have features of myelodysplastic syndrome and myeloproliferative neoplasms. They have shared biology and shared driver mutations, and they represent a very heterogeneous set of patients that present with variable clinical courses and clinical needs. Those patients can’t really fit in one box, and their treatment goals are very different...
So MDS/MPN and overlap syndromes are a group of cancers that have features of myelodysplastic syndrome and myeloproliferative neoplasms. They have shared biology and shared driver mutations, and they represent a very heterogeneous set of patients that present with variable clinical courses and clinical needs. Those patients can’t really fit in one box, and their treatment goals are very different. Some of those patients are more burdened by the disease symptoms and by their spleen and by the morbidity that happens from a big spleen and high disease symptom burden, and they will need different tools for their therapy. So the JAK inhibitors have been validated and studied in myelofibrosis, and they are very effective at reducing spleen and symptoms. And with that rationale, in addition to biological rationale and studying these and showing JAK/STAT-dependent pathway activation in MDS and MPN overlap syndromes. It was practical and pragmatic to use JAK inhibitors in this setting. And there have been multiple efforts that are very admirable to be able to conduct prospective studies in these rare patients. And I did a review of the available literature in this setting. So my conclusions were that JAK inhibitors have activity in a select set of patients who have a proliferative phenotype and have predominantly symptom and spleen-related morbidity. And in these patients, there are true benefits that are measurable. However, it’s probably modest and short-lived. However, it does provide some impetus for more prospective and more combination-based therapies for these patients. Now, this conclusion has been reached by many investigators, and there’s a very prolific portfolio of clinical trials that is ongoing, trying to investigate different JAK inhibitors along with different combinations in patients with MDS and MPN overlap syndromes with a specific phenotype in which we think they will benefit from this therapy. So we’re very excited about this momentum, and hopefully it will lead to better options for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.